BPC-157 for tendons (UK evidence review): what the rodent data actually shows

BPC-157's tendon literature is almost entirely rodent-based. Krivic et al. and Staresinic et al. reported that transected rat Achilles tendons treated with BPC-157 (typically 10 µg/kg or 10 ng/kg intraperitoneally or locally) showed faster functional recovery, improved tenocyte outgrowth in vitro, and better organised collagen fibres on histology versus controls.

Chang et al. extended this to cultured tendon fibroblasts, showing dose-dependent increases in cell migration and F-actin formation, plausibly via upregulation of the growth-hormone receptor on tenocytes. The mechanism is consistent, but every published tendon study is preclinical.

There are no completed randomised human trials of BPC-157 for tendinopathy. UK researchers should treat any human anecdote as uncontrolled. Dosing conventions used in laboratory work are summarised in the BPC-157 dosage UK guide, including U-100 syringe units for a 5 mg vial.

BPC-157 is not licensed by the MHRA and is prohibited in-competition under the WADA S0 category. It is supplied in the UK for laboratory research only.